Institutional analyst price forecasts for Atara Biotherapeutics (NASDAQ: ATRA) generally carry a consensus 12-month target averaging roughly $11.50 per share. Future share price momentum is closely linked to regulatory milestones, commercial partnership distributions, and clinical trial results across its T-cell immunotherapy pipeline.